Brought to you by 
AbbVie, Voyager sign $1.2bn agreement for anti-tau antibodies aimed at CNS diseases; deal later terminated
04 Aug 2020
Executive Summary
AbbVie Inc. and Voyager Therapeutics Inc. are teaming up in the development of vectorized tau antibodies for treating neurodegenerative conditions including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Macromolecule
-
Drug Delivery
-
Biotechnology
- Gene Therapy, Cell Therapy
-
Large Molecule
- Antibodies
Deal Status
- Terminated
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
AbbVie, Voyager sign $1.2bn agreement for anti-tau antibodies aimed at CNS diseases; deal later terminated
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice